A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

  • STATUS
    Recruiting
  • End date
    Jun 2, 2022
  • participants needed
    249
  • sponsor
    Astellas Pharma China, Inc.
Updated on 12 September 2021
mirabegron
incontinence
overactive bladder

Summary

The purpose of this study is to evaluate the efficacy of mirabegron for the treatment of overactive blsdder (OAB) in Chinese participants. This study will also evaluate the safety of mirabegron for the treatment of OAB in Chinese participants, evaluate other efficacy variables of mirabegron for the treatment of OAB and explore different mirabegron starting doses.

Description

The study follows an open-label, randomized, 12-week, prospective, interventional postauthorization design for the treatment of OAB in approximately 249 Chinese participants. Each participant will take part in one 12-week treatment period. Treatments will be administered once daily orally after a meal during a 12-week, open-label treatment period. Study visits will take place at weeks 4, 8 and 12. For 25 mg mirabegron group, a dose escalation to 50 mg is permitted on visit 3 and visit 4 at investigators' discretion. Approximately 10 study sites across China are planned.

Details
Condition Urinary Incontinence, bladder disorder, Overactive Bladder, Urge Incontinence, Bladder Disorders
Treatment mirabegron
Clinical Study IdentifierNCT04562090
SponsorAstellas Pharma China, Inc.
Last Modified on12 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Subject should exhibit symptoms of OAB for at least 12 weeks before initiation of the screening period
Subject should have an average of 8 micturitions/24 hours
Subject should have an average of 1 episode of grade 3 or 4 (PPIUS) urgency or urgency incontinence/24 hours, during a 3-day micturition diary period
Female subject is not pregnant and at least one of the following conditions apply
Not a woman of childbearing potential (WOCBP)
WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 30 days after final IP administration
Female subject must agree not to breastfeed starting at screening and throughout the study period and for 30 days after final IP administration
Female subject must not donate ova starting at first dose of investigational product (IP) and throughout the study period and for 30 days after final IP administration
Male subject with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and 30 days after final IP administration
Male subject must not donate sperm during the treatment period and for 30 days after final IP administration
Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 30 days after final IP administration
Subject agrees not to participate in another interventional study while participating in the present study, defined as 28 days prior screening until completion of the last study visit

Exclusion Criteria

Exclusion at Visit 1/Week -2 (Screening)
Subject has stress urinary incontinence as a predominant symptom
Subject has neurogenic detrusor overactivity or indicated pathology other than OAB
Subject has an average total daily urine volume > 3000 mL (as recorded in a 3-day voiding diary period)
Subject has indwelling catheter or practices intermittent self-catheterization
Subject as monosymptomatic enuresis
Subject has lower urinary tract stones or clinically significant kidney stones requiring treatment
Subject has post void residual (PVR) volume of 100 mL or a clinically significant lower urinary tract obstructive disease, except if successfully treated
Subject has suffered from chronic UTI or has had more than 3 ETIs in the 2 months prior to visit 1/week -1 to -2 (screening)
Subject has anatomical anomalies (surgically treated or untreated) that affect lower urinary tract function
Subject with hematuria on dipstick test. In the case of hematuria on dipstick test in a female during menstruation, the test can be repeated before randomization (after the end of menstruation)
Subject has pulse rate 110 beats per minute (bpm) or <50 bpm
Subject has interstitial cystitis
Subject has moderate or severe renal impairment
Subject has uncontrolled hypertension (sitting systolic blood pressure [SBP] 180 mmHg or diastolic blood pressure [DBP] 110 mmHg)
Subject has corrected QT interval by Fredericia (QTcF) > 440 msec on screening ECG or a risk of QT prolongation (e.g., hypokalemia, long QT syndrome [LQTS] or family history of LQTS or exercise-induced syncope)
Subject's aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is 2 upper limit of normal (ULN) or total bilirubin (TBL) is 1.5 ULN according to age and sex (subjects with Gilbert's syndrome are excepted from the bilirubin threshold)
Subjects previously treated for OAB including medication and nondrug treatment. If the treatment stopped for 2 weeks or more prior to the screening visit, Subjects can be included in the study
Subject has a symptomatic (symptoms can include pain, fever, hematuria, new onset foul-smelling urine) UTI. Note: if the UTI is treated successfully (clinical recovery: confirmed by dipstick test and repeated dipstick test after 14 days [both should be negative]), the subject can be rescreened
Subject has participated in another clinical study (and/or subject has received any investigational therapy within 30 days (or 5 half-lives of the drug, or the limit set by national law, whichever is longer) prior to visit 1/week -1 to -2 (screening)
Subject has a history or presence of any malignancy (previous or current diagnosis of bladder or prostate cancer)
Subject uses any drugs that are sensitive cytochrome P450 2D6 (CYP2D6) substrates with a narrow therapeutic index or sensitive P-glycoprotein (P-gp) substrates after the start of washout
Subject is using or has used prohibited prior and/or concomitant medication(s). In case 1-AR antagonists, 5-reductase inhibitors (5-ARIs) and Phosphodiesterase type 5 inhibitors (PED-Is) are used for Benign Prostatic Hyperplasia(BPH), Subject can be included in the study
Subjects has a positive serology test for hepatitis A virus (HAV) antibodies (immunoglobulin M [IgM]), hepatitis B core (HBc) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, antibodies to human immunodeficiency virus (HIV) or syphilis at screening
Subject has known or suspected hypersensitivity to mirabegron or any components of the formulations used
Subject has constipation as defined by the Rome IV criteria that cannot be successfully treated prior to study entry
Female subject who has been pregnant within 6 months prior to screening or breastfeeding within 3 months prior to screening
Subject is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit
Subject has any condition which makes the subject unsuitable for study participation
Additional Exclusion at Visit 2/Week 0 (Baseline)
Subject has stress urinary incontinence as a predominant symptom
Subject has an average total daily urine volume > 3000 mL (as recorded in a 3-day voiding diary period)
Subject has monosymptomatic enuresis confirmed by the bladder e-diary
Subject suffers from a symptomatic (symptoms can include pain, fever, hematuria, new onset foul-smelling urine) UTI. Note: if a symptomatic UTI is present, all visit 2/week 0 (baseline) assessments must be postponed until the UTI is successfully treated (clinical recovery: confirmed by dipstick test and repeated dipstick test after 14 days [both should be negative]). The postponed visit 2/week 0 (baseline) should be within 14 days of the intended visit 2/week 0 (baseline)
Subject with hematuria on dipstick test. In the case of hematuria on dipstick test in a female during menstruation, the test can be repeated before randomization (after the end of menstruation)
Subject has uncontrolled hypertension (sitting SBP 180 mmHg or DBP 110 mmHg)
Any reason that makes the subject unsuitable for study participation
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note